5-MeO-DBT, also known as 5-methoxy-N,N-dibutyltryptamine, is a serotonin receptor modulator, and a rare substituted tryptamine derivative, which is thought to be a psychoactive substance.

Unlike many other related compounds it exhibits very low efficacy for the 5-HT2A receptor.

5-MeO-DBT was first described in the literature by Alexander Shulgin in his 1997 book TiHKAL (Tryptamines I Have Known and Loved). It was encountered as a novel designer drug by 2019 and was assessed pharmacologically in 2023. The drug is controlled under drug analogue legislation in a number of jurisdictions.

Use and effects In his book TiHKAL (Tryptamines I Have Known and Loved), Alexander Shulgin briefly mentioned 5-MeO-DBT and described it as a known compound with unknown activity. Relatedly, the properties and effects of 5-MeO-DBT are unknown. In any case, related drugs like dibutyltryptamine (DBT) and 4-HO-DPT have been reported to yield disappointing effects.

Interactions

Pharmacology Pharmacodynamics + Target Affinity (Ki, nM) 5-HT1A 337 (Ki)267 ()106% () 5-HT2A 562 (Ki)620a ()18%a () 5-HT2C 3,130 (Ki)2,400a ()76%a () 1,180 (Ki)2,120 () Notes: The smaller the value, the more avidly the drug interacts with the site. Footnotes: a = Stimulation of formation. Sources:

Based on limited evidence, 5-MeO-DBT acts as a non-selective serotonin receptor agonist with the highest potency and efficacy at the 5-HT1A receptor. It has a similar potency to 5-MeO-MiPT for this target. The substance, unlike many other substituted tryptamines, acts as a very weak and low efficacy partial agonist for the 5-HT2A receptor. Among the group of related tryptamine analogues it also displayed the lowest efficacy for the 5-HT2C receptor.

5-MeO-DBT decreased locomotor activity and failed to substitute for the discriminative stimulus effects of DOM in rodent drug discrimination tests.

Chemistry Analogues Analogues of 5-MeO-DBT include dibutyltryptamine (DBT), 4-HO-DBT, 5-MeO-DMT, 5-MeO-DET, 5-MeO-DPT, 5-MeO-DiPT, 5-MeO-DALT, 5-MeO-DsBT, and 5-MeO-MBT, among others. https://isomerdesign.com/pihkal/read/tk/36

History 5-MeO-DBT was first described in the literature by Alexander Shulgin in his 1997 book TiHKAL (Tryptamines I Have Known and Loved). It was encountered as a novel designer drug by 2019.

Society and culture Legal status United States Alabama 5-MeO-DBT was made schedule I at the state level in Alabama on September 13, 2024.

See also Substituted tryptamine

References

External links 5-MeO-DBT - Isomer Design